Spectrum disorder

CaringKind to Host the 27th Annual Forget-Me-Not Gala, on June 12th at The Pierre, with a Star-Studded Lineup Including David Hyde Pierce, Peter Gabriel, Q-Tip, and more

Retrieved on: 
Monday, June 5, 2023
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Cotton swab, Music, Education, Master of Ceremonies (Sweden), Schneps Media, Dementia, Picower Institute for Learning and Memory, Tony, Public policy, Research, MIT, Ceremony, Spectrum disorder, Lenox Hill Hospital, MD, Patient, Isabel, Memory, National Bioscience Award for Career Development, Learning, Psychiatry, Master, Grammy Awards, Neurology, The Pierre, Caregiver, Gala, Northwell Health, Rock and Roll Hall of Fame, Nursing, Residential care, Alzheimer's disease, Reverberation

The Forget-Me-Not Gala is a way for CaringKind to continue to raise essential funds to support the myriad of programs they offer.

Key Points: 
  • The Forget-Me-Not Gala is a way for CaringKind to continue to raise essential funds to support the myriad of programs they offer.
  • David Hyde Pierce, who received the Tony's Isabelle Stevenson Award for his longtime advocacy and support for Alzheimer's care and research, will serve as the Master of Ceremonies for the evening.
  • At the Gala, CaringKind will honor three outstanding individuals and groups for their significant contributions to the Alzheimer's community.
  • For further information about the Forget-Me-Not Gala, including donations, please visit www.caringkindnyc.org/gala or contact Courtney Dawson at 646-744-2932 or [email protected] .

Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases

Retrieved on: 
Tuesday, February 28, 2023
Spectrum disorder, Total permanent disability insurance, Collection, Disease, Self-assessment, Biomarker, Research, Algorithm, Patient, Rare disease, Digital, GMG, Fatigue, Alexion, Communication, Pharmaceutical industry, Medical imaging, NMOSD, Neurology

The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.

Key Points: 
  • The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.
  • gMG and NMOSD are chronic severe diseases in which progression is complex and critical to monitor.
  • Digital biomarkers are patient-generated physiological and behavioral measures that are collected from digital devices like smartphones and processed by algorithms.
  • Scoping phases have been conducted for both programs to identify clinically meaningful digital biomarkers to monitor patients living with NMOSD or gMG.

Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases

Retrieved on: 
Tuesday, February 28, 2023
Spectrum disorder, Total permanent disability insurance, Collection, Disease, Self-assessment, Biomarker, Research, Algorithm, Patient, Rare disease, Digital, GMG, Fatigue, Alexion, Communication, Pharmaceutical industry, Medical imaging, NMOSD, Neurology

The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.

Key Points: 
  • The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.
  • gMG and NMOSD are chronic severe diseases in which progression is complex and critical to monitor.
  • Digital biomarkers are patient-generated physiological and behavioral measures that are collected from digital devices like smartphones and processed by algorithms.
  • Scoping phases have been conducted for both programs to identify clinically meaningful digital biomarkers to monitor patients living with NMOSD or gMG.

LAPIX Therapeutics Inc. Announces a Successful Conclusion of its Pre-IND Meeting Request with the U.S. FDA

Retrieved on: 
Thursday, January 26, 2023
MS, Food, Multiple sclerosis, Immune system, Spectrum disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Neuro, NMOSD, EAE, MOGAD, Immune tolerance, Degenerative disease, Therapy, Pharmaceutical industry, Vaccine

BOSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharma company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases and oncology, today announced the successful outcome of its pre-IND meeting request with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • BOSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharma company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases and oncology, today announced the successful outcome of its pre-IND meeting request with the U.S. Food and Drug Administration (FDA).
  • The meeting’s objective was to achieve alignment with the FDA on LAPIX’s IND-enabling plan for its novel, first-in-class, immune tolerance restoration small molecule, LPX-TI641, under development for neuro-autoimmune indications such as multiple sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD).
  • We also expect it to be safe enough for early and long-term use,” said Anas M. Fathallah, Ph.D., President, and Co-founder of LAPIX.
  • “The outcome of this meeting request supports LAPIX’s IND-enabling plan and we now have a path forward to the clinic.”

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

Retrieved on: 
Thursday, January 5, 2023
Autoimmune disease, ASX, MD, Research, Rheumatoid arthritis, Immunotherapy, Tissue, Autoantibody, CSL, Degenerative disease, Lupus, Aplastic anemia, Autoimmune hepatitis, SLE, Antibody, NMO, Autoimmunity, Spectrum disorder, Vaccine

Autoantibodies are immune system proteins that can mistakenly target the body’s own organs and tissues.

Key Points: 
  • Autoantibodies are immune system proteins that can mistakenly target the body’s own organs and tissues.
  • Autoantibodies can target almost every part of the body and are found in a wide range of autoimmune diseases, such as lupus, autoimmune hepatitis, aplastic anemia, and rheumatoid arthritis among many others.
  • “The unique capabilities of our transchromosomic cows and DiversitAb™ platform continue to prove the power of polyclonals to address complex and very difficult to treat autoimmune diseases.”
    Anti-idiotypic polyclonal antibodies are highly specialized antibodies that bind to other antibodies specifically “bad acting” antibodies associated with many autoimmune diseases such as type 1 diabetes, NMO or systemic lupus erythematosus (SLE).
  • “Often, multiple autoantibodies are responsible for an autoimmune response, and our DiversitAb™ platform has proven its ability to create an ‘antidote’ antibody treatment that can "disarm” those harmful autoantibodies without a broad immunosuppressive effect — having implications across a wide variety of autoimmune diseases.”

HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab

Retrieved on: 
Tuesday, October 11, 2022
Ophthalmology, Degenerative disease, Neonatal Fc receptor, Patient, RMB, Immunology, Annual report, NBP, Multimedia, Myasthenia gravis, KRX, Neurology, CEO, Nature, Duane syndrome, Spectrum disorder, INN, Korea Exchange, Clinical trial, Intellectual property, Graves' ophthalmopathy, Urologic disease, CSPC, Autoimmunity, Pharmaceutical industry, Fine chemical

The deal grants NBP Pharma the exclusive rights to develop and commercialize batoclimab in Greater China including mainland of China, HongKong, Macau,and Taiwan.

Key Points: 
  • The deal grants NBP Pharma the exclusive rights to develop and commercialize batoclimab in Greater China including mainland of China, HongKong, Macau,and Taiwan.
  • "We are pleased to have reached this agreement with Harbour BioMed," said Cuilong Zhang, CEO of CSPC through the press release by Harbour BioMed.
  • "Batoclimab is a promising innovative drug, and we hope to accelerate its clinical development, manufacturing, registration and commercialization in China, so as to benefit the patients in China better and earlier,"he added.
  • "HanAll welcomes CSPC to join our journey to develop innovative medicines for patients in China.

HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner

Retrieved on: 
Tuesday, October 4, 2022
Degenerative disease, Neonatal Fc receptor, INN, Immunology, Ophthalmology, CEO, Spectrum disorder, Roivant Sciences, Duane syndrome, KRX, Patient, Urologic disease, Graves' ophthalmopathy, Myasthenia gravis, Neurology, Pharmaceutical industry, Fine chemical

Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402)

Key Points: 
  • Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402)
    Batoclimab (formerly known as HL161BKN) and HL161ANS originated from HanAll.
  • Both batoclimab and HL161ANS compounds were licensed to Roivant Sciences in regions including North America, South America, and Europe in 2017.
  • HL161ANS demonstrated deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein in animal studies.
  • "We are excited with the potential contribution our second FcRn inhibitor HL161ANS can make to patients suffering from severe autoimmune diseases," said Sean Jeong, M.D., CEO of HanAll Biopharma.

Ophthalmic Images Now Available through the Academy IRIS® Registry, Curated at Scale by Verana Health's VeraQ Engine

Retrieved on: 
Thursday, September 29, 2022
People, American Academy, Center, Master of Science, Medicare, Research, IRIS, Patient, GA, Physician, Technology, Spectrum disorder, American Urological Association, Disease, Geographic atrophy, RWD, Organization, CMS, OCT, Multiple sclerosis, Doctor of Philosophy, HCPS, SAN, Associate, Associated Students of the University of Washington, Medicine, Health, Comparison, VTC, Registry, CATT, Population, Data management, MIPS, MIGS, American Academy of Neurology, 2021 Essex County Council election, Data, Clinical trial, E350, Artificial intelligence, Poster, Macular degeneration, Ophthalmic, EHR, AAO, Millennium, Academy, Machine learning, Biomarker, Bergen County Academies, Deep learning, Quality of life, Solution, HCP, Diagnosis, DEX, AMD, University, Medical imaging, Medical device, Pharmaceutical industry, MD, Ophthalmology

SAN FRANCISCO , Sept. 29, 2022 /PRNewswire/ -- Verana Health® announced today the introduction of ophthalmic images into its VeraQ™ population health data engine. The ~3.5 million images—spanning optical coherence tomography (OCT), fundus autofluorescence, color fundus photography, and more—are being incorporated into the Academy IRIS® Registry. This data is managed by Verana Health via VeraQ, where it is linked with de-identified electronic health record (EHR) data and curated with clinician oversight and artificial intelligence (AI), such as machine learning (ML), to produce quality data variables and Ophthalmology Qdata™ modules. These image-derived variables and Qdata modules—being introduced to the ophthalmic community at the Academy's Annual Meeting (AAO 2022)—will be selectively available in the future to academic research institutions participating in the IRIS Registry Analytic Center Consortium and life sciences organizations, respectively.

Key Points: 
  • American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) extends data footprint by making available data from more than 3.5 million images of eyes.
  • SAN FRANCISCO, Sept. 29, 2022 /PRNewswire/ -- Verana Health announced today the introduction of ophthalmic images into its VeraQ population health data engine.
  • The ~3.5 million imagesspanning optical coherence tomography (OCT), fundus autofluorescence, color fundus photography, and moreare being incorporated into the Academy IRIS Registry.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, quality data modules, Qdata.

Devic's Syndrome Treatment Global Market Report 2022: Soliris (Eculizumab) to Fuel Considerable Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022
Health, Other Health, Death, Antibody, Woman, Alexion, Neuromyelitis optica spectrum disorder, Autoantibody, C5a, Inflammation, CNS, Degenerative disease, DST, Population, Neuron, Diagnosis, Growth, Complement component 5, Geography, Brain, Prevalence, Chapter Five, Chapter Three, Pain, MedImmune, Plasma protein binding, Patient, National Multiple Sclerosis Society, Spectrum disorder, Autoimmune disease, Severe cognitive impairment, Syndrome, Awareness, CAGR, Chapter Six, Spinal cord, Protein, Type, Chugai Pharmaceutical Co., Optic nerve, NMOSD, Immune system, Paralysis, Lithium, Vaccine, Fine chemical, Pharmaceutical industry, Medical imaging, Fertilizer, Eculizumab, Devic

The key factors responsible for growth of global Devic's syndrome treatment market are rising awareness & prevalence related to orphan diseases, recent launch of first-target specific drug Soliris (Eculizumab) and strong drug pipeline expected to provide significant growth in the market.

Key Points: 
  • The key factors responsible for growth of global Devic's syndrome treatment market are rising awareness & prevalence related to orphan diseases, recent launch of first-target specific drug Soliris (Eculizumab) and strong drug pipeline expected to provide significant growth in the market.
  • This report comprises in-depth information related to the Devic's Syndrome treatment market along with major factors affecting or assisting market such as opportunities, drivers, & restraints.
  • This report covered detailed info related to the global Devic's syndrome treatment market segmented based on drug type, and geography.
  • Global Devic's Syndrome Treatment (DST) Market: Market Dynamics and Future Outlook
    Chapter 4.

New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Retrieved on: 
Friday, June 24, 2022
Health, Pharmaceutical, Loss of Sensation, Science, Patient, NMOSD, EC, Union, Aquaporin 4, B cell, All European Academies, Royal commission, European Academy of Neurology, Quality of life, Attack, NMO, CD19, Optic nerve, Astrocyte, Pain scale, Spinal cord, Woman, Autoimmunity, Safety, Risk, Instagram, Congress, Twitter, Forward-looking statement, LinkedIn, Experiment, Brain, Poster, Severe cognitive impairment, European Commission, Central nervous system, Neuromyelitis optica spectrum disorder, Autoantibody, Inflammation, Nasdaq, Cell, EMEA, Courage, Adult, Head, Paralysis, U.S. Securities and Exchange Commission, Spectrum disorder, EAN, Physician, Pharmaceutical industry, Medical device, Vaccine, Wood drying, EU, Facebook

These data are being presented during the 8th Congress of the European Academy of Neurology (EAN), June 25-28 in Vienna.

Key Points: 
  • These data are being presented during the 8th Congress of the European Academy of Neurology (EAN), June 25-28 in Vienna.
  • Fewer NMOSD-related hospitalisations were reported among those receiving UPLIZNA compared to those treated with placebo (mean, EU: 1.0 vs 2.0; non-EU: 1.0 vs 1.33).
  • NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes.
  • Baranello RJ, Avasarala, JR. Neuromyelitis optica spectrum disorders with and without aquaporin 4 antibody: Characterization, differential diagnosis, and recent advances.